Tech Company Financing Transactions
Ablacon Funding Round
Zeus Health and private investors participated in a $30 million Series B funding round for Ablacon. The round was announced by the company on 1/8/2021.
Transaction Overview
Company Name
Announced On
1/8/2021
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors
Zeus Health (Lead Investor)
Proceeds Purpose
Ablacon plans to use the new funds to advance the company's product portfolio and continue expanding patient access to the CE Marked Ablamap system.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
4800 Wadsworth Blvd. 310
Wheat Ridge, CO 80033
USA
Wheat Ridge, CO 80033
USA
Phone
Website
Email Address
Overview
Ablacon has built a premier machine intelligence system to quantitatively and qualitatively understand and treat atrial fibrillation (AF).Their technology visualizes in real-time what is going on in the heart. They compute the electrographic flow which allows to treat atrial fibrillation faster, more precisely and more reliably.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Duke Rohlen
Chief Operating Officer
Martin Grasse
VP - Finance
Lana Kasyanchik
Browse more venture capital transactions:
Prev: 1/8/2021: Kira Pharmaceuticals venture capital transaction
Next: 1/8/2021: Aspen RxHealth venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs